Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1967 1
1970 1
1977 1
1979 1
1980 1
1981 3
1984 1
1989 1
1991 2
1992 1
1993 1
1994 2
1995 1
1997 3
1998 1
1999 1
2001 4
2002 1
2003 3
2004 5
2005 6
2006 3
2007 2
2008 6
2009 5
2010 2
2011 3
2012 7
2013 7
2014 5
2015 4
2016 2
2017 4
2018 4
2019 1
2020 6
2021 3
2022 2
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Genovese MC, et al. Among authors: cardillo te. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247. N Engl J Med. 2016. PMID: 27028914 Free article. Clinical Trial.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, Sontag A, Grond S, Issa M, Lu X, Cardillo T, Holzwarth K, Thyssen JP. Bieber T, et al. Among authors: cardillo t. J Dermatolog Treat. 2023 Dec;34(1):2161812. doi: 10.1080/09546634.2022.2161812. J Dermatolog Treat. 2023. PMID: 36546346 Free article.
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, Sun L, Cardillo T, Nunes FP, Reich K. Silverberg JI, et al. Among authors: cardillo t. JAMA Dermatol. 2021 Jun 1;157(6):691-699. doi: 10.1001/jamadermatol.2021.1273. JAMA Dermatol. 2021. PMID: 33978711 Free PMC article. Clinical Trial.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: cardillo t. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
Novel Peptide Camptothecin Drug-linkers for Potent ADCs-Letter.
Goldenberg DM, Sharkey RM, Govindan SV, Cardillo TM. Goldenberg DM, et al. Among authors: cardillo tm. Mol Cancer Ther. 2022 Jan;21(1):237. doi: 10.1158/1535-7163.MCT-21-0212. Mol Cancer Ther. 2022. PMID: 34996865 No abstract available.
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, Janes J, Sun L, Chen S, Silverberg JI. Reich K, et al. Among authors: cardillo t. Br J Dermatol. 2023 Feb 10;188(2):208-217. doi: 10.1093/bjd/ljac057. Br J Dermatol. 2023. PMID: 36763879 Clinical Trial.
102 results